SFPQ rescues F508del-CFTR expression and function in cystic fibrosis bronchial epithelial cells

被引:0
|
作者
Parameet Kumar
Dharmendra Kumar Soni
Chaitali Sen
Mads B. Larsen
Krystyna Mazan-Mamczarz
Yulan Piao
Supriyo De
Myriam Gorospe
Raymond A. Frizzell
Roopa Biswas
机构
[1] School of Medicine,Department of Anatomy, Physiology and Genetics
[2] Uniformed Services University of the Health Sciences,Department of Cell Biology
[3] University of Pittsburgh,Laboratory of Genetics and Genomics
[4] School of Medicine,Department of Anatomy, Physiology and Genetics
[5] National Institute on Aging,undefined
[6] National Institutes of Health,undefined
[7] School of Medicine,undefined
[8] Uniformed Services University of the Health Sciences,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Cystic fibrosis (CF) occurs as a result of mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which lead to misfolding, trafficking defects, and impaired function of the CFTR protein. Splicing factor proline/glutamine-rich (SFPQ) is a multifunctional nuclear RNA-binding protein (RBP) implicated in the regulation of gene expression pathways and intracellular trafficking. Here, we investigated the role of SFPQ in the regulation of the expression and function of F508del-CFTR in CF lung epithelial cells. We find that the expression of SFPQ is reduced in F508del-CFTR CF epithelial cells compared to WT-CFTR control cells. Interestingly, the overexpression of SFPQ in CF cells increases the expression as well as rescues the function of F508del-CFTR. Further, comprehensive transcriptome analyses indicate that SFPQ plays a key role in activating the mutant F508del-CFTR by modulating several cellular signaling pathways. This is the first report on the role of SFPQ in the regulation of expression and function of F508del-CFTR in CF lung disease. Our findings provide new insights into SFPQ-mediated molecular mechanisms and point to possible novel epigenetic therapeutic targets for CF and related pulmonary diseases.
引用
收藏
相关论文
共 50 条
  • [31] Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR
    Taylor-Cousar, Jennifer L.
    Jain, Manu
    Barto, Tara Lynn
    Haddad, Tarik
    Atkinson, Jeffrey
    Tian, Simon
    Tang, Rui
    Marigowda, Gautham
    Waltz, David
    Pilewski, Joseph
    JOURNAL OF CYSTIC FIBROSIS, 2018, 17 (02) : 228 - 235
  • [32] Phosphorylation of the Chaperone-Like HspB5 Rescues Trafficking and Function of F508del-CFTR
    Degrugillier, Fanny
    Aissat, Abdel
    Pruliere-Escabasse, Virginie
    Bizard, Lucie
    Simonneau, Benjamin
    Decrouy, Xavier
    Jiang, Chong
    Rotin, Daniela
    Fanen, Pascale
    Simon, Stephanie
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (14) : 1 - 18
  • [33] A Chemical Corrector Modifies the Channel Function of F508del-CFTR
    Chiaw, Patrick Kim
    Wellhauser, Leigh
    Huan, Ling Jun
    Ramjeesingh, Mohabir
    Bear, Christine E.
    MOLECULAR PHARMACOLOGY, 2010, 78 (03) : 411 - 418
  • [34] Extracellular phosphate enhances the function of F508del-CFTR rescued by CFTR correctors
    Saint-Criq, Vinciane
    Wang, Yiting
    Delpiano, Livia
    Lin, JinHeng
    Sheppard, David N.
    Gray, Michael A.
    JOURNAL OF CYSTIC FIBROSIS, 2021, 20 (05) : 843 - 850
  • [35] CFTR potentiators partially restore channel function to A561E-CFTR, a cystic fibrosis mutant with a similar mechanism of dysfunction as F508del-CFTR
    Wang, Yiting
    Liu, Jia
    Loizidou, Avgi
    Bugeja, Luc A.
    Warner, Ross
    Hawley, Bethan R.
    Cai, Zhiwei
    Toye, Ashley M.
    Sheppard, David N.
    Li, Hongyu
    BRITISH JOURNAL OF PHARMACOLOGY, 2014, 171 (19) : 4490 - 4503
  • [36] INFECTIONS IN F508DEL-CFTR HOMOZYGOUS CYSTIC FIBROSIS PATIENTS TREATED WITH LUMACAFTOR/IVACAFTOR IN A NORTHERN ITALIAN CYSTIC FIBROSIS CENTER
    Colombo, C.
    Cariani, L.
    Sottotetti, S.
    Bisogno, A.
    Castcllazzi, L.
    Nazzari, E.
    Cigana, C.
    Bragonzi, A.
    PEDIATRIC PULMONOLOGY, 2018, 53 : 165 - 166
  • [37] Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation
    Cholon, Deborah M.
    Esther, Charles R., Jr.
    Gentzsch, Martina
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2016, 1 (03): : 235 - 243
  • [38] Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR A Clinical Trial
    Sagel, Scott D.
    Khan, Umer
    Heltshe, Sonya L.
    Clancy, John P.
    Borowitz, Drucy
    Gelfond, Daniel
    Donaldson, Scott H.
    Moran, Antoinette
    Ratjen, Felix
    VanDalfsen, Jill M.
    Rowe, Steven M.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2021, 18 (01) : 75 - 83
  • [39] Chemical rescue of ΔF508-CFTR mimics genetic repair in cystic fibrosis bronchial epithelial cells
    Singh, Om V.
    Pollard, Harvey B.
    Zeitlin, Pamela L.
    MOLECULAR & CELLULAR PROTEOMICS, 2008, 7 (06) : 1099 - 1110
  • [40] SAFETY AND PHARMACOKINETICS OF N91115 IN PATIENTS WITH CYSTIC FIBROSIS HOMOZYGOUS FOR THE F508DEL-CFTR MUTATION
    Donaldson, S. H.
    PEDIATRIC PULMONOLOGY, 2015, 50 : 293 - 293